Breaking down barriers: is intestinal mucus degradation by Akkermansia muciniphila beneficial or harmful?
Infection and Immunity · 09.09.2025 · 93 (9)
DOI: 10.1128/iai.00503-24 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Infection and Immunity, erschienen am 09.09.2025. Verfasst von Anna M Tingler und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Regenerative Medicine & Cell Biology, Medical University of South Carolina, Charleston, South Carolina, USA. Hauptthemen laut MEDLINE: Gastrointestinal Microbiome, Mucins, Intestinal Mucosa, Akkermansia. Die Arbeit wurde bisher 54-mal zitiert (Crossref) und nennt 370 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIGMS NIH HHS, NIDDK NIH HHS, National Institute of Diabetes and Digestive and Kidney Diseases.
Abstract (Originalsprache)
Akkermansia muciniphila is a specialized mucin-degrading bacterium that plays a pivotal role in gut health and disease. This review examines the dualistic nature of A. muciniphila mucin degradation, exploring its potential benefits and risks. As a mucin specialist, A. muciniphila uses glycosyl hydrolases and mucinases to degrade mucins, producing metabolites like short-chain fatty acids (SCFAs), branched-chain fatty acids (BCFAs), succinate, and other compounds. These metabolites benefit host health and cross-feed other commensal microbes, such as butyrate producers. A. muciniphila levels are inversely correlated with several disease states, such as obesity, diabetes, and inflammatory states, and administration of A. muciniphila has been found by several groups to restore and maintain gut homeostasis. However, under certain conditions, such as low dietary fiber or conditions with an altered gut microbiota, excessive mucin degradation by A. muciniphila can compromise the mucus barrier, increasing susceptibility to inflammation, infection, and pathogenic overgrowth. Elevated A. muciniphila levels have been associated with various diseases and medications, including graft versus host disease (GVHD) and irradiation, and shown to exacerbate infections by enteric pathogens. The context-dependent effects of A. muciniphila and mucin degradation underscore the need for a nuanced understanding of its interactions with the host and microbial community. This review aims to provide a balanced perspective on the implications of gut microbial mucus degradation, highlighting that it can be good, and it can be bad depending on the context.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Regenerative Medicine & Cell Biology, Medical University of South Carolina, Charleston, South Carolina, USA.
- Department of Pharmacology & Immunology, Medical University of South Carolina, Charleston, South Carolina, USA.
ORCID-Profile: Anna M Tingler, Melinda A Engevik
Förderung
- NIGMS NIH HHS
- NIDDK NIH HHS
- National Institute of Diabetes and Digestive and Kidney Diseases
- National Institute of General Medical Sciences
Zitieren
APA
Tingler, A. M., & Engevik, M. A. (2025). Breaking down barriers: is intestinal mucus degradation by Akkermansia muciniphila beneficial or harmful?. Infection and Immunity, 93(9). https://doi.org/10.1128/iai.00503-24
Vancouver
Tingler AM, Engevik MA. Breaking down barriers: is intestinal mucus degradation by Akkermansia muciniphila beneficial or harmful?. Infection and Immunity. 2025;93(9). doi:10.1128/iai.00503-24
BibTeX
@article{Tingler2025,
author = {Tingler, Anna M and Engevik, Melinda A},
title = {Breaking down barriers: is intestinal mucus degradation by Akkermansia muciniphila beneficial or harmful?},
journal = {Infection and Immunity},
year = {2025},
volume = {93},
number = {9},
doi = {10.1128/iai.00503-24}
}
EUVIMED